- Home
- BNBX vs CANF Comparison
BNBX vs CANF Comparison
Compare BNBX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNBX
- CANF
- Stock Information
- Founded
- BNBX 1983
- CANF 1994
- Country
- BNBX United States
- CANF Israel
- Employees
- BNBX N/A
- CANF N/A
- Industry
- BNBX Other Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- BNBX Consumer Discretionary
- CANF Health Care
- Exchange
- BNBX Nasdaq
- CANF Nasdaq
- Market Cap
- BNBX 5.5M
- CANF 5.0M
- IPO Year
- BNBX N/A
- CANF N/A
- Fundamental
- Price
- BNBX $2.46
- CANF $0.33
- Analyst Decision
- BNBX
- CANF Strong Buy
- Analyst Count
- BNBX 0
- CANF 2
- Target Price
- BNBX N/A
- CANF $6.75
- AVG Volume (30 Days)
- BNBX 55.4K
- CANF 19.2M
- Earning Date
- BNBX 12-16-2025
- CANF 11-27-2025
- Dividend Yield
- BNBX N/A
- CANF N/A
- EPS Growth
- BNBX N/A
- CANF N/A
- EPS
- BNBX 211.51
- CANF N/A
- Revenue
- BNBX $3,743,063.00
- CANF $560,000.00
- Revenue This Year
- BNBX $57.08
- CANF $461.72
- Revenue Next Year
- BNBX $40.00
- CANF N/A
- P/E Ratio
- BNBX $0.01
- CANF N/A
- Revenue Growth
- BNBX 55.60
- CANF N/A
- 52 Week Low
- BNBX $2.13
- CANF $0.28
- 52 Week High
- BNBX $190.80
- CANF $2.35
- Technical
- Relative Strength Index (RSI)
- BNBX N/A
- CANF 36.80
- Support Level
- BNBX N/A
- CANF $0.28
- Resistance Level
- BNBX N/A
- CANF $0.36
- Average True Range (ATR)
- BNBX 0.00
- CANF 0.05
- MACD
- BNBX 0.00
- CANF 0.00
- Stochastic Oscillator
- BNBX 0.00
- CANF 19.67
About BNBX Applied DNA Sciences Inc. Common Stock
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).